ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Breast Cancer
-
-
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
-
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
-
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
-
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
-
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
-
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
-
Biomarkers in Tissue Samples From Older Women With Breast Cancer
-
Breast Cancer Awareness Month: Advancing Breast Cancer Research through Clinical Trials
Research progress in breast cancer is saving lives, improving treatments, and offering hope to millions of people. Yet breast cancer remains a significant public health challenge, underscoring the continued need for research, earlier detection, and more effective treatment options. Breast cancer is the most common cancer in American women, after skin cancers, accounting for about…
-
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE
A Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with SignateraTM MRD-Guided CDK4/6 Inhibitor Therapy in ER-Positive/HER2-Negative Early-Stage Breast Cancer Trial will utilize Natera’s ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentech’s oral SERD, with the objective to spare patients from unnecessary CDK4/6…